Drug eluting stents do not value the Swiss study
A Swiss study found that, overall, his drug-eluting stents do not provide value for money and that would still be the case if they were considerably cheaper. However, they are useful when used to treat patients with high risk of clogged arteries with stents or bypass fitted. These are the results of Professor Matthias Pfisterer, University Hospital Basel, Switzerland, and colleagues and the study was published this week in The Lancet. Coated stents are tiny tubes with drugs designed network of open clogged arteries subjected to support and restore blood flow.Stent is believed to collapse first. However, drug-eluting stents controversial with some studies suggest that it could be the result of blood clots. Matias and his colleagues conducted a study of 18 months on the
economics of drug-eluting stents. This test was part of the Basel Stent KostenEffekitvits (CART), which were built and 826 patients with drug-eluting stents and bare metal stent in a ratio of 2 to 1, respectively (545-281).Interventions against a measure of benefits. To assess the benefits, the researchers asked patients to improve the quality of life complete (EQ-5D) questionnaire, which is able to work in the years of patient quality-adjusted life years (QALYs), a combination of quality and durability. The low-risk patients those with 3.0 mm diameter stents or vascular origin (ie, the ships had been in their natural environment, unlike the other grafted were fitted to a part of the body and bypass surgery).
small arteries, the stent patients required less than 3.0
mm in diameter and were mounted stents, had bypass surgery. The results showed that the total costs for patients with drug-eluting stents were higher (€ 11 808 per patient, or about $ 17,000) than patients with bare-metal stents (€ 10 450 per patient, s in the amount of approximately $ 15,000) resulting in an average cost more for the stent to € 1.358 (approx. $ 2000).Was € 40,467 (about $ 58,000). ICER costs
Pages: [1] 2